---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-017728"
form_type: "8-K"
ticker: "PHGE"
cik: "0001739174"
company_name: "BiomX Inc."
filed_at: "2025-02-27T23:59:59+00:00"
generated_at: "2026-05-26T02:21:17.782464+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# BiomX raises $12M in combined offerings; funds BX004 Phase 2b to Q1 2026

## Summary
- Gross proceeds ~$12M from registered direct offering, private placement, and warrant exercise at $0.9306/share.
- Investors include Deerfield Management, Cystic Fibrosis Foundation, and Nantahala Capital.
- Proceeds to fund BX004 Phase 2b in CF; topline results expected Q1 2026.
- Existing warrants reduced from $2.311 to $0.9306; new warrants issued for 100% of exercised shares.
- Also advancing BX211 Phase 2 readout in diabetic foot osteomyelitis this quarter.

## SEC filing metadata
- accession: 0001213900-25-017728
- form_type: 8-K
- ticker: PHGE
- cik: 0001739174
- company_name: BiomX Inc.
- filed_at: 2025-02-27T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1739174/000121390025017728/0001213900-25-017728-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1739174/000121390025017728/ea0232201-8k_biomx.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-017728
- JSON: https://secwatch.observer/filing/0001213900-25-017728.json
- Plain text: https://secwatch.observer/filing/0001213900-25-017728.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.